Skip to content

Novel Association of Cholesterol Ester Storage Disease Due to Lysosomal Acid Lipase Deficiency and Non-Alcoholic Fatty Liver Disease: A Prospective Clinical Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01791452
Enrollment
Unknown
Registered
2013-02-15
Start date
Unknown
Completion date
Unknown
Last updated
2013-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholesterol Ester Storage Disease, Non-alcoholic Fatty Liver Disease

Brief summary

Non-alcoholic fatty liver disease (NAFLD) is a world-wide problem with a global prevalence estimated at 1.5 billion people. It is characterised by significant diversity and phenotypic heterogeneity. Morbidity rates are estimated at 20% to 30% in Western adults, increasing to 90% in patients who are morbidly obese or diabetic. Risk factors in non-obese NAFLD patients are of especial practical and theoretical importance. Cholesterol Ester Storage Disease (CESD) is an autosomal recessive chronic disease of variable phenotype, caused by a deficiency in lysosomal acid lipase (LAL) and characterized by accumulation of fat in tissues and organs. Hepatic accumulation of fat in this disorder can cause hepatomegaly with varying degrees of damage varying from steatosis to fibrosis, elevated aminotransaminases, and isolated splenomegaly. Since the contribution of LAL deficiency to non-obese NAFLD is poorly understood, the investigators propose to evaluating the association between NAFLD and LAL deficiency in a prospective study in our population.

Interventions

None listed

Sponsors

Assy Nimer
Lead SponsorOTHER_GOV

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Age between 18-80 years; * BMI 25-40; * Fatty liver disease (bright liver, hepatomegaly by ultrasound (Liver span \> 15 cm mid clavicle line), splenomegaly (\>13 cm) or both.

Exclusion criteria

* Alcohol abuse\>30 gm/day, or \> 70 gram per week; * Soft drink abuse; * Drugs known to cause fatty liver; * Chronic hepatitis (B and C); * Biliary liver disease; * Autoimmune hepatitis; * HIV; * Genetic/Metabolic liver disease (Wilson, alpha-1 antitrypsin, CF); * Failure to give informed consent

Design outcomes

Primary

MeasureTime frame
liver ultrasound, ultrasound Doppler of the common carotid artery, hepatic Fibroscan evaluation (transient elastography) for assessment of steatosis and fibrosisyear

Countries

Israel

Contacts

Primary ContactNimer Assy, M
assy.n@ziv.health.gov.il+972-4-6828442

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026